Your browser is no longer supported. Please, upgrade your browser.
MYMD [NASD]
MyMD Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.22 Insider Own13.29% Shs Outstand37.63M Perf Week18.08%
Market Cap290.70M Forward P/E- EPS next Y- Insider Trans0.30% Shs Float32.67M Perf Month-13.77%
Income-29.80M PEG- EPS next Q- Inst Own17.30% Short Float2.81% Perf Quarter28.40%
Sales- P/S- EPS this Y68.80% Inst Trans21.12% Short Ratio4.34 Perf Half Y74.83%
Book/sh0.68 P/B11.24 EPS next Y- ROA-88.70% Target Price- Perf Year108.74%
Cash/sh0.40 P/C18.88 EPS next 5Y- ROE-96.40% 52W Range3.30 - 10.48 Perf YTD91.96%
Dividend- P/FCF- EPS past 5Y65.40% ROI- 52W High-27.10% Beta0.49
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low131.52% ATR0.69
Employees4 Current Ratio7.60 Sales Q/Q- Oper. Margin- RSI (14)48.36 Volatility10.64% 8.88%
OptionableYes Debt/Eq0.00 EPS Q/Q81.00% Profit Margin- Rel Volume0.92 Prev Close7.10
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume211.40K Price7.64
Recom- SMA20-7.54% SMA50-4.14% SMA20023.39% Volume193,551 Change7.61%
Nov-23-21 09:25AM  
Nov-18-21 09:15AM  
Nov-16-21 09:25AM  
Nov-15-21 09:45AM  
Oct-26-21 10:30AM  
Oct-19-21 10:30AM  
Oct-05-21 10:00AM  
Sep-22-21 11:00AM  
Sep-13-21 10:00AM  
Sep-09-21 10:15AM  
Aug-24-21 10:17AM  
Aug-23-21 08:47AM  
Aug-10-21 02:30PM  
10:30AM  
Aug-05-21 10:30AM  
Jul-27-21 09:15AM  
Jul-07-21 09:00AM  
Jun-07-21 10:02AM  
May-17-21 09:00AM  
May-12-21 09:00AM  
May-10-21 09:00AM  
Apr-28-21 10:13AM  
Apr-22-21 09:20AM  
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, engages in the development of drug candidates to treat autoimmune, and aging and age-related diseases. It is developing MYMD-1, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel diseases, as well as to treat age-related illnesses such as, frailty and sarcopenia. The company is also developing Supera-CBD, a synthetic preclinical cannabidiol derivative that targets CB2 receptors. The company is based in Baltimore, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rivard PaulEVP of Operations, GCNov 23Buy6.0315,00090,450215,000Nov 24 12:56 PM